002393 力生制药
已收盘 05-12 15:00:00
资讯
新帖
简况
力生制药(002393)披露高级管理人员减持股份预披露公告,5月8日股价下跌0.54%
证券之星 · 05-08
力生制药(002393)披露高级管理人员减持股份预披露公告,5月8日股价下跌0.54%
力生制药:使用闲置自有资金进行现金管理
证券之星 · 05-08
力生制药:使用闲置自有资金进行现金管理
力生制药:研发费用比上年同期减少35.03%
证券之星 · 04-27
力生制药:研发费用比上年同期减少35.03%
股市必读:力生制药(002393)4月24日收盘跌5.14%,主力净流入432.57万元
证券之星 · 04-27
股市必读:力生制药(002393)4月24日收盘跌5.14%,主力净流入432.57万元
力生制药(002393)2026年一季报简析:净利润同比下降6.14%
证券之星 · 04-25
力生制药(002393)2026年一季报简析:净利润同比下降6.14%
力生制药(002393)披露2026年一季度报告,4月23日股价下跌1.83%
中金财经 · 04-24
力生制药(002393)披露2026年一季度报告,4月23日股价下跌1.83%
天津发展(00882):力生制药一季度归母净利润约5188.3万元,同比减少6.14%
智通财经 · 04-24
天津发展(00882):力生制药一季度归母净利润约5188.3万元,同比减少6.14%
力生制药季度归属股东净利润达5188万元
美股速递 · 04-24
力生制药季度归属股东净利润达5188万元
图解力生制药一季报:第一季度单季净利润同比下降6.14%
证券之星 · 04-24
图解力生制药一季报:第一季度单季净利润同比下降6.14%
力生制药(002393.SZ)发布一季度业绩,归母净利润5188.3万元,同比下降6.14%
智通财经 · 04-23
力生制药(002393.SZ)发布一季度业绩,归母净利润5188.3万元,同比下降6.14%
力生制药(002393)3月31日股东户数2.61万户,较上期增加19.68%
证券之星 · 04-23
力生制药(002393)3月31日股东户数2.61万户,较上期增加19.68%
股市必读:力生制药(002393)4月3日董秘有最新回复
证券之星 · 04-07
股市必读:力生制药(002393)4月3日董秘有最新回复
力生制药:公司截至目前尚未收到来自中东地区碘化钾的订单
证券之星 · 04-03
力生制药:公司截至目前尚未收到来自中东地区碘化钾的订单
力生制药:2025年度每10股派6元转增2股
证券之星 · 03-27
力生制药:2025年度每10股派6元转增2股
力生制药(002393)2025年年报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 03-26
力生制药(002393)2025年年报简析:营收净利润同比双双增长,盈利能力上升
天津发展:力生制药年度归母净利润4.16亿元 同比增长125.59%
新浪港股 · 03-25
天津发展:力生制药年度归母净利润4.16亿元 同比增长125.59%
天津发展控股有限公司 - 力生制药全年总营业收入达13.9亿元人民币
美股速递 · 03-25
天津发展控股有限公司 - 力生制药全年总营业收入达13.9亿元人民币
图解力生制药年报:第四季度单季净利润同比增长198.13%
证券之星 · 03-25
图解力生制药年报:第四季度单季净利润同比增长198.13%
力生制药(002393.SZ)发布2025年度业绩,归母净利润4.16亿元,增长125.59%
智通财经 · 03-24
力生制药(002393.SZ)发布2025年度业绩,归母净利润4.16亿元,增长125.59%
股市必读:力生制药(002393)3月23日收盘跌5.74%,主力净流出1259.88万元
证券之星 · 03-24
股市必读:力生制药(002393)3月23日收盘跌5.74%,主力净流出1259.88万元
加载更多
公司概况
公司名称:
天津力生制药股份有限公司
所属行业:
医药制造业
上市日期:
2010-04-23
主营业务:
天津力生制药股份有限公司的主营业务是医药产品研发、生产和销售。公司的主要产品是寿比山®吲达帕胺片、三鱼®氨酚咖匹林片、希福尼®头孢地尼分散片、友好®麻仁软胶囊、生化®氢化可的松琥铂酸钠冻干粉针和碳酸氢钠片、盖胃平片、麻仁润肠丸、虎力散片。公司坚持以科技创新赋能产业高质量发展,创新能力和可持续发展能力持续增强,产品包括心脑血管、消化、抗感染、呼吸、跌打等15大类297个药品,拥有注册商标189个。
发行价格:
45.00
{"stockData":{"symbol":"002393","market":"SZ","secType":"STK","nameCN":"力生制药","latestPrice":16.38,"timestamp":1778569410000,"preClose":16.68,"halted":0,"volume":2766483,"delay":0,"changeRate":-0.018,"floatShares":300000000,"shares":309000000,"eps":1.3364,"marketStatus":"已收盘","change":-0.3,"latestTime":"05-12 15:00:00","open":16.63,"high":16.65,"low":16.33,"amount":45418400,"amplitude":0.0192,"askPrice":16.38,"askSize":0,"bidPrice":16.37,"bidSize":6,"shortable":0,"etf":0,"ttmEps":1.3364,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":5,"adr":0,"adjPreClose":16.68,"symbolType":"stock","openAndCloseTimeList":[[1778549400000,1778556600000],[1778562000000,1778569200000]],"highLimit":18.35,"lowLimit":15.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":308964215,"isCdr":false,"pbRate":1.12,"roa":"--","peRate":12.256809,"roe":"1.12%","epsLYR":1.62,"committee":0.787083,"marketValue":5061000000,"turnoverRate":0.0092,"status":1,"floatMarketCap":4918000000},"requestUrl":"/m/hq/s/002393","defaultTab":"news","newsList":[{"id":"2633843972","title":"力生制药(002393)披露高级管理人员减持股份预披露公告,5月8日股价下跌0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633843972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633843972?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:27","pubTimestamp":1778232446,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,力生制药报收于16.5元,较前一交易日下跌0.54%,最新总市值为50.98亿元。近日,力生制药发布《关于公司高级管理人员减持股份预披露公告》。公告显示,公司高级管理人员郭晓燕女士持有公司股份124,320股,占公司总股本的0.0402%,占剔除回购专用账户后总股本的0.0403%。郭晓燕女士计划在公告披露之日起15个交易日后的3个月内,通过集中竞价方式减持不超过22,042股,占其持股总数的25%,占公司剔除回购专用账户后总股本的0.0072%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800031184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633488468","title":"力生制药:使用闲置自有资金进行现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2633488468","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633488468?lang=zh_cn&edition=full","pubTime":"2026-05-08 11:36","pubTimestamp":1778211395,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药(002393)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,面对持续破净局面,公司以现金理财方式获得的收益vs回购增厚EPS,哪种对股东价值更优?请您务必尽职答复为盼!力生制药回复:投资者您好,公司为提高公司资金使用效率,合理利用自有资金,增加公司收益,在保证公司日常经营资金需求及资金流动性、安全性前提下使用闲置自有资金进行的现金管理。感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800017387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002393","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630200356","title":"力生制药:研发费用比上年同期减少35.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630200356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630200356?lang=zh_cn&edition=full","pubTime":"2026-04-27 11:36","pubTimestamp":1777260972,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药04月27日在投资者关系平台上答复投资者关心的问题。研发费用比上年同期减少35.03%,其主要原因:研发项目付款节点不均衡;一季度业绩波动是转型的阶段性表现,公司正通过渠道扩张、新品放量、研发攻坚、资本赋能四维发力,夯实长期增长基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700017707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002393","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630019331","title":"股市必读:力生制药(002393)4月24日收盘跌5.14%,主力净流入432.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630019331","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630019331?lang=zh_cn&edition=full","pubTime":"2026-04-27 06:39","pubTimestamp":1777243149,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,力生制药报收于21.4元,下跌5.14%,换手率2.78%,成交量6.96万手,成交额1.48亿元。当日关注点来自交易信息汇总:力生制药股价连续4日下跌,4月24日收跌5.14%至21.4元,前10个交易日主力资金累计净流出超3593万元。来自业绩披露要点:力生制药2026年一季度主营收入同比下降10.16%,归母净利润同比下降6.14%,扣非净利润降幅扩大至12.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700006736.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630878024","title":"力生制药(002393)2026年一季报简析:净利润同比下降6.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630878024","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630878024?lang=zh_cn&edition=full","pubTime":"2026-04-25 06:23","pubTimestamp":1777069439,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期力生制药发布2026年一季报。根据财报显示,力生制药净利润同比下降6.14%。截至本报告期末,公司营业总收入3.32亿元,同比下降10.16%,归母净利润5188.3万元,同比下降6.14%。然而去年的净利率为30.37%,算上全部成本后,公司产品或服务的附加值极高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500020663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629862056","title":"力生制药(002393)披露2026年一季度报告,4月23日股价下跌1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629862056","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629862056?lang=zh_cn&edition=full","pubTime":"2026-04-24 08:16","pubTimestamp":1776989790,"startTime":"0","endTime":"0","summary":"近日,天津力生制药股份有限公司披露《2026年第一季度报告》。报告显示,报告期内实现营业收入332,282,846.72元,同比下降10.16%;归属于上市公司股东的净利润为51,882,970.53元,同比下降6.14%;扣除非经常性损益后的净利润为46,869,507.40元,同比下降12.08%。总资产为5,533,055,376.69元,较上年度末减少0.92%;归属于上市公司股东的所有者权益为4,605,756,501.87元,较上年度末减少0.48%。经营活动产生的现金流量净额为988,720.31元,同比增长201.14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260424/32170281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK0028","002393","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629613108","title":"天津发展(00882):力生制药一季度归母净利润约5188.3万元,同比减少6.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629613108","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629613108?lang=zh_cn&edition=full","pubTime":"2026-04-24 06:20","pubTimestamp":1776982841,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天津发展(00882)发布力生制药2026年第一季度业绩,营业收入约3.32亿元,同比减少10.16%;归属于母公司所有者的净利润约5188.3万元,同比减少6.14%;基本每股收益0.2元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00882","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192630681","title":"力生制药季度归属股东净利润达5188万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192630681","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192630681?lang=zh_cn&edition=full","pubTime":"2026-04-24 06:12","pubTimestamp":1776982331,"startTime":"0","endTime":"0","summary":"天津发展控股有限公司旗下子公司天津力生制药股份有限公司公布最新季度业绩,归属公司股东的净利润达到5188万元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00882","BK0188","002393","BK0239","BK1232","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629528548","title":"图解力生制药一季报:第一季度单季净利润同比下降6.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629528548","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629528548?lang=zh_cn&edition=full","pubTime":"2026-04-24 02:08","pubTimestamp":1776967693,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药2026年一季报显示,一季度公司主营收入3.32亿元,同比下降10.16%;归母净利润5188.3万元,同比下降6.14%;扣非净利润4686.95万元,同比下降12.08%;负债率16.15%,投资收益330.62万元,财务费用-633.88万元,毛利率55.32%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400005709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629884526","title":"力生制药(002393.SZ)发布一季度业绩,归母净利润5188.3万元,同比下降6.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629884526","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629884526?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:34","pubTimestamp":1776936853,"startTime":"0","endTime":"0","summary":"智通财经APP讯,力生制药(002393.SZ)发布2026年第一季度报告,第一季度,公司实现营业收入3.32亿元,同比下降10.16%。归属于上市公司股东的净利润5188.3万元,同比下降6.14%。归属于上市公司股东的扣除非经常性损益的净利润4686.95万元,同比下降12.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629884562","title":"力生制药(002393)3月31日股东户数2.61万户,较上期增加19.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629884562","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629884562?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:32","pubTimestamp":1776936763,"startTime":"0","endTime":"0","summary":"证券之星消息,近日力生制药披露,截至2026年3月31日公司股东户数为2.61万户,较2月28日增加4286.0户,增幅为19.68%。在化学制药行业个股中,力生制药股东户数低于行业平均水平,截至3月31日,化学制药行业平均股东户数为3.5万户。从股价来看,2026年2月28日至2026年3月31日,力生制药区间涨幅为8.58%,在此期间股东户数增加4286.0户,增幅为19.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300048256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","002393","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625059656","title":"股市必读:力生制药(002393)4月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2625059656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625059656?lang=zh_cn&edition=full","pubTime":"2026-04-07 02:24","pubTimestamp":1775499854,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,力生制药报收于23.68元,下跌1.99%,换手率2.8%,成交量7.0万手,成交额1.66亿元。虽然研发人员会有些腼腆,但可以大胆尝试董秘: 尊敬的投资者您好,感谢您分享的宝贵建议。交易信息汇总资金流向4月3日主力资金净流出996.76万元,占总成交额5.99%;游资资金净流出132.8万元,占总成交额0.8%;散户资金净流入1129.55万元,占总成交额6.79%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700000957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002393","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624428653","title":"力生制药:公司截至目前尚未收到来自中东地区碘化钾的订单","url":"https://stock-news.laohu8.com/highlight/detail?id=2624428653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624428653?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:42","pubTimestamp":1775202128,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药(002393)04月03日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,关于中东碘化钾缺货,公司有收到来自中东地区的订单吗力生制药回复:投资者您好,公司截至目前尚未收到来自中东地区碘化钾的订单,感谢关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300026156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002393","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622821051","title":"力生制药:2025年度每10股派6元转增2股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821051","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622821051?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:51","pubTimestamp":1774615867,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药03月26日在投资者关系平台上答复投资者关心的问题。在2025年度,公司实施了以总股本256,886,863股为基数,向全体股东每10股派发现金股利6.00元(含税),实际分配利润154,132,117.80元,占2025年度归属于上市公司股东净利润的37.03%,同时每10股转增2股,以回馈广大股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700046134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002393","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000421","title":"力生制药(002393)2025年年报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000421","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622000421?lang=zh_cn&edition=full","pubTime":"2026-03-26 06:07","pubTimestamp":1774476437,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期力生制药发布2025年年报。截至本报告期末,公司营业总收入13.92亿元,同比上升4.18%,归母净利润4.16亿元,同比上升125.59%。本报告期力生制药盈利能力上升,毛利率同比增幅0.35%,净利率同比增幅118.2%。该数据高于大多数分析师的预期,此前分析师普遍预期2025年净利润为盈利4.11亿元左右。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600006119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622128540","title":"天津发展:力生制药年度归母净利润4.16亿元 同比增长125.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622128540","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622128540?lang=zh_cn&edition=full","pubTime":"2026-03-25 08:19","pubTimestamp":1774397940,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 天津发展(00882)发布力生制药(002393.SZ)截至2025年12月31日止年度业绩,该公司营业收入为13.92亿元,同比增长4.18%。归属于上市公司股东的净利润为4.16亿元,同比增长125.59%。基本每股收益为1.62元。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-25/doc-inhsecsh3726855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["00882","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190843722","title":"天津发展控股有限公司 - 力生制药全年总营业收入达13.9亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1190843722","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190843722?lang=zh_cn&edition=full","pubTime":"2026-03-25 06:08","pubTimestamp":1774390094,"startTime":"0","endTime":"0","summary":"天津发展控股有限公司近日披露,其旗下核心医药板块——力生制药在上一财年实现总营业收入13.9亿元人民币。这一业绩凸显了公司在医药制造领域的稳健表现和市场竞争力。力生制药作为天津发展的重要子公司,其业务进展对集团整体战略布局具有关键影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK1232","BK0188","BK0239","002393","00882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622092372","title":"图解力生制药年报:第四季度单季净利润同比增长198.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622092372","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622092372?lang=zh_cn&edition=full","pubTime":"2026-03-25 01:37","pubTimestamp":1774373854,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药2025年年报显示,当年度公司主营收入13.92亿元,同比上升4.18%;归母净利润4.16亿元,同比上升125.59%;扣非净利润1.69亿元,同比上升63.62%;其中2025年第四季度,公司单季度主营收入3.85亿元,同比上升23.16%;单季度归母净利润4554.3万元,同比上升198.13%;单季度扣非净利润4179.91万元,同比上升1363.13%;负债率16.54%,投资收益3.25亿元,财务费用-4863.99万元,毛利率55.26%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500003169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064024","title":"力生制药(002393.SZ)发布2025年度业绩,归母净利润4.16亿元,增长125.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064024","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621064024?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:19","pubTimestamp":1774354790,"startTime":"0","endTime":"0","summary":"智通财经APP讯,力生制药 发布2025年年度报告,该公司营业收入为13.92亿元,同比增长4.18%。归属于上市公司股东的净利润为4.16亿元,同比增长125.59%。基本每股收益为1.62元。此外,拟向全体股东每10股派发现金红利6元(含税),送红股0股(含税),以资本公积金向全体股东每10股转增2股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"力生制药(002393.SZ)发布2025年度业绩,归母净利润4.16亿元,增长125.59%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621085259","title":"股市必读:力生制药(002393)3月23日收盘跌5.74%,主力净流出1259.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621085259","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621085259?lang=zh_cn&edition=full","pubTime":"2026-03-24 02:14","pubTimestamp":1774289653,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘,力生制药报收于20.54元,下跌5.74%,换手率2.93%,成交量7.33万手,成交额1.52亿元。当日关注点来自交易信息汇总:力生制药3月23日收盘报20.54元,跌5.74%,已连续3日下跌。前10个交易日中,主力资金累计净流出819.6万元,股价累计下跌5.45%;融资余额累计减少396.95万元,融券余量累计减少300股。3月23日资金流向显示:主力资金净流出1259.88万元,游资资金净流入414.99万元,散户资金净流入844.89万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400002037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778576481568,"stockEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":-0.1256},{"period":"3month","weight":-0.0558},{"period":"6month","weight":-0.0446},{"period":"1year","weight":0.2341},{"period":"ytd","weight":-0.0393}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0599},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0562},{"period":"1year","weight":0.2642},{"period":"ytd","weight":0.0645}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"天津力生制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"26060人(较上一季度增加19.68%)","perCapita":"11520股","listingDate":"2010-04-23","address":"天津市西青区西青经济技术开发区赛达北一道16号","registeredCapital":"30896万元","survey":" 天津力生制药股份有限公司的主营业务是医药产品研发、生产和销售。公司的主要产品是寿比山®吲达帕胺片、三鱼®氨酚咖匹林片、希福尼®头孢地尼分散片、友好®麻仁软胶囊、生化®氢化可的松琥铂酸钠冻干粉针和碳酸氢钠片、盖胃平片、麻仁润肠丸、虎力散片。公司坚持以科技创新赋能产业高质量发展,创新能力和可持续发展能力持续增强,产品包括心脑血管、消化、抗感染、呼吸、跌打等15大类297个药品,拥有注册商标189个。","listedPrice":45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"力生制药,002393,力生制药股票,力生制药股票老虎,力生制药股票老虎国际,力生制药行情,力生制药股票行情,力生制药股价,力生制药股市,力生制药股票价格,力生制药股票交易,力生制药股票购买,力生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}